B. Riley Wealth Advisors’s AbCellera Biologics ABCL Stock Holding History

B. Riley Wealth Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-500	Closed	-$1.64K	–	917
2026 Q1	$1.64K	Buy	+500	New	+$1.8K	﹤0.01%	892
2025 Q4	–	Sell	-500	Closed	-$2.52K	–	1022
2025 Q3	$2.52K	Buy	+500	New	+$2.2K	﹤0.01%	1072
2024 Q4	–	Sell	-34,000	Closed	-$88.4K	–	1137
2024 Q3	$88.4K	Buy	34,000 +12,500	+58%	+$34.6K	﹤0.01%	1216
2024 Q2	$63.6K	Buy	21,500 +11,000	+105%	+$41.6K	﹤0.01%	1336
2024 Q1	$48.3K	Sell	10,500 -9,000	-46%	-$45.9K	﹤0.01%	1399
2023 Q4	$111K	Buy	19,500 +9,000	+86%	+$41.7K	﹤0.01%	1316
2023 Q3	$48.3K	Buy	+10,500	New	+$63.9K	﹤0.01%	1399

Other funds holding ABCL

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

CMF

Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return

DRP

Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

HOWA

Heritage Oak Wealth Advisors Santa Rosa Beach, Florida $340M AUM 29.73% 1-Year Est. Return

XML Financial Bethesda, Maryland $1.37B AUM 28.49% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

B. Riley Wealth Advisors's ABCL Position: Q2 2026 in Review

B. Riley Wealth Advisors sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 500 shares — an estimated $1.64K sold.

B. Riley Wealth Advisors first reported a position in ABCL in Q3 2023 and held it in 7 quarters. The position peaked at $111K in Q4 2023. 27 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

B. Riley Wealth Advisors reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
B. Riley Wealth Advisors sold 500 AbCellera Biologics shares in Q2 2026, an estimated $1.64K.
B. Riley Wealth Advisors first reported a position in AbCellera Biologics in Q3 2023 and held it in 7 quarters.
B. Riley Wealth Advisors's AbCellera Biologics position peaked at $111K in Q4 2023.
27 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.